Amphivena Therapeutics

Amphivena Therapeutics is a biotechnology startup established in 2012 and headquartered in South San Francisco, California. The company's focus is on immuno-oncology, aiming to empower cancer patients with dual-action biologics through its ReSTORE platform. This platform is designed to combat immune suppression and stimulate T cell effector function in cancer patients. By incorporating elements of avidity, target selectivity, and enhanced safety within a single molecule, Amphivena Therapeutics can engineer the biologics to include additional features for solid tumor targeting and direct tumor cell elimination. In September 2019, Amphivena Therapeutics secured a significant $62.00M Series C investment. The funding was provided by a group of prominent investors including MPM Capital, Qiming Venture Partners, Aju IB Investment, Clough Capital, Franklin Berger, Mérieux Equity Partners, ND Capital, Solasta Ventures, Industrial Investors Group, and Newton Investment Management. This investment signifies confidence in the potential of Amphivena Therapeutics and its innovative approach to immuno-oncology, positioning the startup for continued growth and impact in the healthcare and biotechnology industries.